Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Pazopanib for progressive desmoid tumors

Maud Toulmonde • 1 Jun 2018
ASCO 2018
Sarcoma Methotrexate Pazopanib Vinblastine
DESMOPAZ

There have previously been no randomized trials assessing systemic therapy activity for progressive desmoid tumors. Here, Maud Toulmonde, MD, of the Institut Bergonié, Bordeaux, France, discusses the aims, methods and results of the DESMOPAZ trial (NCT01876082). This French Sarcoma Group trial investigated the use of pazopanib vs. IV methotrexate/vinblastine in desmoid tumors. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

More from Maud Toulmonde

1:45
PEMBROSARC: pembrolizumab combinations for advanced sarcoma
Maud Toulmonde • 1 Jun 2018

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals